Filterlex Medical successfully raised $3 million for Its Embolic Protection Device

An Israeli startup, Filterlex Medical which is developing a next-generation embolic protection device, made an announcement last week that they have completed a Series funding round raising a total of $3 million in the capital.

The Yokneam-based firm has developed the Captis embolic protection device which mitigates the risk of stroke, as well as, other complications during catheter-based structural heart procedures.

At the EuroPCR 2019 innovation competition in Paris, Captis was honored with the best innovation award & was also awarded a grant of $200,000 by the Jon DeHaan Foundation, an organization providing support to individuals & firms devoted to the developments in cardiovascular medicine.

Captis is a full-body embolic protection device which works by securing to the aorta & deflecting, capturing & removing embolic particles. Particles which enter the blood flow during catheter-based heart procedures can give rise to a variety of complications, those which reach the brain can result in neurological deficiencies & even stroke, while those which reach the distal organs can cause kidney injury & ischemia.

The device is distinctive since it requires no additional arterial access & doesn’t interfere with the procedure workflow, according to the statement.

The Chief Executive Officer at Filterlex Medical, Sigal Eli stated that out of the 80 competing projects, there was a selection of only 6 innovations for the final competition. The international recognition provided will enable us to present our product to the international cardiologists & we believe that it will become a must-have best-in-class device for benefitting patients undergoing left-heart procedures.

The EuroPCR conference, which was hosted in France by the European Association of Percutaneous Cardiovascular Interventions is a course in Interventional Cardiovascular Medicine with more than 11 thousand participants from around the world.

Filterlex Medical was discovered in June 2016 at the Alon MedTech Ventures incubator & initiated operating independently in August 2018.